Hanmi Pharma (128940.KS) Q1 2026: R&D at 16.6% Narrows Operating Profit 9%
*Beijing Hanmi's 22% segment margin and ₩93 billion in free cash flow cushion a quarter where accelerated R&D spending — not operational weakness — produced the year-on-year earnings shortfall.*
Source: Quarterly Report (Q1 FY2026, 17th Fiscal Year) — Filed May 15, 2026 with DART | Consolidated Financial Statements | Unit: ₩ billions
